Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.46 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.46 |
| ▸ | BLM | P54132 | 2/20 | 0.46 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 9/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11896861 | 0.83 | ALDH1A1 (0.35) | — | |
| SCHEMBL11039888 | 0.83 | ALDH1A1 (0.35) | — | |
| SCHEMBL16115350 | 0.80 | TSHR (0.42) | TSHRGABRR1GABRR2BLMGABRR3 | |
| SCHEMBL6371257 | 0.80 | TSHR (0.42) | TSHRGABRR1GABRR2BLMGABRR3 | |
| SCHEMBL1489361 | 0.80 | TSHR (0.48) | TSHRGABRR1GABRR2BLMGABRR3 | |
| SCHEMBL6371264 | 0.80 | TSHR (0.42) | TSHRGABRR1GABRR2BLMGABRR3 | |
| SCHEMBL14964626 | 0.78 | ALDH1A1 (0.32) | — | |
| SCHEMBL28726001 | 0.78 | TSHR (0.50) | TSHRGABRR1GABRR2BLMGABRR3 | |
| SCHEMBL931344 | 0.77 | TSHR (0.45) | TSHRGABRR1GABRR2BLMGABRR3 | |
| SCHEMBL29089162 | 0.77 | TSHR (0.39) | TSHRGABRR1GABRR2BLMGABRR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2963031-A2 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | Zynerba Pharmaceuticals, Inc. (US) | 2016-01-06 | — | — | EP | claimed |
| US-8980942-B2 | Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same | ZYNERBA PHARMACEUTICALS, INC. (US) | 2015-03-17 | — | — | US | claimed |
| US-20120289484-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ALLTRANZ INC. | 2012-11-15 | — | — | US | claimed |
| EP-2215071-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | AllTranz Inc. (US) | 2010-08-11 | — | — | EP | claimed |
| WO-2009073633-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ALLTRANZ INC. (US) | 2009-06-11 | — | — | WO | claimed |
| US-20090143462-A1 | Products of Tetrahydrocannabinol, Compositions Comprising Prodrugs of Tetrahydrocannabinol and Methods of Using the Same | ALLTRANZ (US) | 2009-06-04 | — | — | US | claimed |
| US-20240217942-A1 | PRODRUGS OF TETRAHYDROCANNABINOL COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS, INC. (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240083866-A1 | PRODRUGS OF TETRAHYDROCANNABINOL COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS, INC. (US) | 2024-03-14 | — | — | US | disclosed |
| US-20230414518-A1 | RAPIDLY INFUSING CANNABINOID COMPOSITIONS, PROCESSES OF MANUFACTURE, AND METHODS OF USE | Orcosa Inc. (US) | 2023-12-28 | — | — | US | disclosed |
| WO-2023224960-A1 | RAPIDLY INFUSING CANNABINOID COMPOSITIONS, PROCESSES OF MANUFACTURE, AND METHODS OF USE | Orcosa Inc. (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20230321119-A1 | STICK COMPOSITION CONTAINING CANNABINOIDS | Orcosa Inc. (US) | 2023-10-12 | — | — | US | disclosed |
| EP-4255403-A1 | RAPIDLY INFUSING CANNABINOID COMPOSITIONS, PROCESSES OF MANUFACTURE, AND METHODS OF USE | Orcosa Inc. (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20220194916-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS, INC. (US) | 2022-06-23 | — | — | US | disclosed |
| US-8227627-B2 | Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same | ALLTRANZ INC. (US) | 2012-07-24 | — | — | US | disclosed |
| EP-2473475-A1 | USE OF CANNABIDIOL PRODRUGS IN TOPICAL AND TRANSDERMAL ADMINISTRATION WITH MICRONEEDLES | AllTranz Inc. (US) | 2012-07-11 | — | — | EP | disclosed |
| WO-2011026144-A1 | USE OF CANNABIDIOL PRODRUGS IN TOPICAL AND TRANSDERMAL ADMINISTRATION WITH MICRONEEDLES | ALLTRANZ INC. (US) | 2011-03-03 | — | — | WO | disclosed |
| US-20110052694-A1 | USE OF CANNABIDIOL PRODRUGS IN TOPICAL AND TRANSDERMAL ADMINISTRATION WITH MICRONEEDLES | ALLTRANZ INC. (US) | 2011-03-03 | — | — | US | disclosed |
| EP-2215071-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | AllTranz Inc. (US) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009073633-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ALLTRANZ INC. (US) | 2009-06-11 | — | — | WO | disclosed |
| US-20090143462-A1 | Products of Tetrahydrocannabinol, Compositions Comprising Prodrugs of Tetrahydrocannabinol and Methods of Using the Same | ALLTRANZ (US) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289484-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | TSHR 1736/4885GABRR1 1625/4885GABRR2 1771/4885 |
| US-20110052694-A1 | USE OF CANNABIDIOL PRODRUGS IN TOPICAL AND TRANSDERMAL ADMINISTRATION WITH MICRONEEDLES | PNLIP, CNR2, CNR1 | TSHR 2425/4885GABRR1 4128/4885GABRR2 4202/4885 |
| US-20240083866-A1 | PRODRUGS OF TETRAHYDROCANNABINOL COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | TSHR 1840/4885GABRR1 1751/4885GABRR2 1922/4885 |
| US-20090143462-A1 | Products of Tetrahydrocannabinol, Compositions Comprising Prodrugs of Tetrahydrocannabinol and Methods of Using the Same | CNR2, CNR1, FAAH | TSHR 1869/4885GABRR1 1653/4885GABRR2 1776/4885 |
| US-20220194916-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | TSHR 1736/4885GABRR1 1625/4885GABRR2 1771/4885 |
| US-20240217942-A1 | PRODRUGS OF TETRAHYDROCANNABINOL COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | TSHR 1840/4885GABRR1 1751/4885GABRR2 1922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.